Annex to 24-27 February 2025 CHMP Agenda

Frequently asked questions (FAQs) : How to create and submit an annual safety report and respond to related requests for information - CTIS Training Programme - Module 18

Frequently asked questions (FAQs): How to create, submit and withdraw a Clinical Trial Application - CTIS Training Programme - Module 10

Minutes - PDCO minutes of the 12-15 November 2024 meeting

Vitrolife IVF media - Procedural steps and scientific information after initial consultation

Human medicines European public assessment report (EPAR): Tarceva, erlotinib, Date of authorisation: 19/09/2005, Revision: 34, Status: Authorised

Human medicines European public assessment report (EPAR): ReFacto AF, moroctocog alfa, Date of authorisation: 13/04/1999, Revision: 41, Status: Authorised

Human medicines European public assessment report (EPAR): Toviaz, fesoterodine, Date of authorisation: 20/04/2007, Revision: 30, Status: Authorised

Human medicines European public assessment report (EPAR): Ryzodeg, insulin degludec,insulin aspart, Date of authorisation: 21/01/2013, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Viramune, nevirapine, Date of authorisation: 04/02/1998, Revision: 45, Status: Authorised